Flu was again worse than covid this winter. Is that pattern here to stay?

Influenza overtook COVID-19 in both infections and hospitalizations during the recent winter respiratory season, and the two viruses are showing similar levels of virulence. For investors, the shift points to potential impacts on healthcare utilization, vaccine and antiviral demand, and hospital staffing/operations, but the article provides no quantitative metrics suggesting immediate, market-moving implications.

Analysis

Market structure: A winter where influenza overtakes COVID shifts revenue from pandemic-era COVID specialists toward traditional vaccine makers, diagnostics and retail pharmacies. Direct winners: diagnostics/rapid-test makers (Abbott ABT, Quidel QDEL), pharmacies (CVS, WBA) and legacy flu vaccine producers (Sanofi SNY, GSK GSK); losers: pure-play mRNA COVID vaccine dependency (Moderna MRNA) and COVID therapeutics if demand falls. Expect pricing power to favor high-margin diagnostics and OTC sales while COVID booster pricing and volumes compress across 2026 vs. 2021–23 peaks.

Risk assessment: Tail risks include a novel COVID variant restoring demand (low-probability, high-impact in 3–6 months) or CDC shifting vaccine guidance that reallocates funding; regulatory action on test reimbursement could knock 20–40% off diagnostics revenue quickly. Near-term (weeks) effects are visible in hospital admissions and retail OTC sales; medium-term (1–3 quarters) affects Q2–Q3 earnings; long-term (1–3 years) could restructure vaccine market share. Hidden dependencies: hospital staffing constraints and insurance reimbursement lag could mute revenue flow despite higher admissions.

Trade implications: Implement concentrated longs in diagnostics and retail health: ABT and QDEL as core longs for 3–9 months, paired with tactical short exposure to MRNA and select COVID-focused biotech. Options: buy 3–6 month call spreads on ABT/QDEL and 3-month put spreads on MRNA to cap cost. Rotate overweight into healthcare services (HCA) if hospitalization trends persist for two consecutive weeks; trim travel/leisure cyclicals (airlines) if respiratory season remains elevated.

Contrarian angles: Consensus may underprice the magnitude of steady-state flu demand and overprice permanent decline of COVID revenue streams; MRNA’s valuation assumes recurring high booster uptake—if uptake falls 40% vs. 2023, downside >30%. Historical parallels: post-2010 seasonal influenza normalization reduced emergency-use product premiums rapidly. Unintended consequence: lower COVID cases could temporarily boost elective procedures and hospital margins, benefiting providers even as vaccine revenues fall.

Key Decisions for Investors

• Establish a 2–3% long position in Abbott Laboratories (ABT) over 3–9 months, and hedge with a 1% stop-loss if shares fall >12% intraperiod; consider 6-month call spread (buy 1x, sell 1x 10–15% OTM) to limit capital and target 25–40% upside.
• Initiate a 1–2% long position in Quidel (QDEL) for 3–6 months to capture rapid-test demand; complement with a 3-month 5–10% OTM call spread sized to risk no more than 0.5% portfolio exposure.
• Open a 1–2% short or put-spread position on Moderna (MRNA) (3-month 10% OTM put spread) anticipating 20–40% lower booster volumes vs. 2023; exit if CDC issues a broad new booster recommendation or if weekly COVID hospitalizations rise >30% week-over-week.
• Rotate 3–5% portfolio weight toward healthcare services (HCA) and retail pharmacies (CVS, WBA) over the next 4–12 weeks if two consecutive weekly datapoints show flu hospitalizations above 5-year seasonal average; reduce travel/leisure exposure (airlines DAL, AAL) by 2–4% in the same window.